生物制药公司MapLight Therapeutics宣布，其针对阿尔茨海默病精神病症状的候选药物ML-007C-MA已获得美国食品药品监督管理局（FDA）授予的快速通道资格。这一认定将加速该药物的临床开发与审评进程，为患者提供更早获得创新疗法的可能。
ML-007C-MA是一种针对特定神经机制的新型治疗药物，旨在缓解阿尔茨海默病患者常见的精神病性症状，如幻觉、妄想和激越行为。快速通道资格的获得，意味着FDA认可该药物在未满足医疗需求领域的潜在价值，并将通过更频繁的沟通、滚动审评等机制支持其研发。
公司表示将积极推进后续临床试验，力争早日为患者带来新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.